Encoded Therapeutics

Private

#Epilepsy #Dravet Syndrome #Neurological Disorders

Clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, with lead gene therapy ETX101 for Dravet syndrome.

Company Info

Sector:RNA, Peptide & Gene Therapy

Headquarters:South San Francisco, California, United States

Founded:2017

Website:encoded.com/

Funding Round:Series F

Total Funding:$275M

Funding & Investor Relations

Notable Investors

GV
Arch Venture Partners
a]6z Bio

Upcoming Milestones & Key Dates

2026-09-10

Financing

$275M Series F close announced

2027

Regulatory

Expected IND submission for ETX301

Clinical Development Pipeline

ETX101

Target: SCN1A gene

Dravet Syndrome (SCN1A+)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ETX301

Target: Neurological gene therapy

Post-epileptic encephalopathy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Kartik Ramamoorthi

Co-Founder & CEO

Sean P. Nolan

Chairman of the Board

Andrew Stober

Chief Manufacturing Officer

Careers & Job Openings

See all open roles

Various

South San Francisco, CA

Apply Now →